Clear Creek Financial Management LLC Acquires Shares of 16,138 Novo Nordisk A/S $NVO

Clear Creek Financial Management LLC acquired a new position in shares of Novo Nordisk A/S (NYSE:NVO) in the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 16,138 shares of the company’s stock, valued at approximately $821,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of NVO. True Wealth Design LLC raised its stake in Novo Nordisk A/S by 209.8% in the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after buying an additional 300 shares in the last quarter. Guerra Advisors Inc purchased a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at about $25,000. American National Bank & Trust purchased a new position in shares of Novo Nordisk A/S in the 4th quarter valued at about $28,000. Maseco LLP acquired a new stake in shares of Novo Nordisk A/S during the 4th quarter worth about $29,000. Finally, Strengthening Families & Communities LLC purchased a new stake in Novo Nordisk A/S during the third quarter worth approximately $30,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

NVO opened at $37.52 on Monday. The stock has a market capitalization of $167.51 billion, a PE ratio of 10.81, a P/E/G ratio of 8.85 and a beta of 0.73. The company’s 50 day simple moving average is $41.03 and its 200 day simple moving average is $48.92. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $81.44. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The business had revenue of $12.43 billion during the quarter, compared to analysts’ expectations of $11.97 billion. As a group, sell-side analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Dividend Announcement

The business also recently announced a dividend, which was paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th were given a $1.2751 dividend. The ex-dividend date of this dividend was Monday, March 30th. This represents a dividend yield of 723.0%. Novo Nordisk A/S’s payout ratio is presently 50.43%.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Short interest fell sharply in March (about a 19% drop vs. mid‑March), lowering near‑term bearish pressure and reducing potential short‑covering risk. (Source: recent short‑interest report)
• Positive Sentiment: EMA cleared an update allowing Wegovy injections to be delivered at up to 30°C for 48 hours, which should improve distribution flexibility and lower logistics costs in Europe — a modest operational tailwind. Wegovy EMA approval
• Positive Sentiment: Wegovy’s oral formulation appears to be expanding the obesity treatment market by drawing new patients (not just switching injection users), supporting longer‑term demand potential for Novo’s GLP‑1 franchise. CNBC short on Wegovy pill
• Neutral Sentiment: Positive buy‑and‑hold coverage and listings naming Novo as a top growth stock provide long‑term investor support but do not address near‑term competitive or pricing issues. Yahoo piece on growth thesis
• Neutral Sentiment: Novo Holdings (the controlling shareholder) is adding investments outside pharma (e.g., superconductors), which is a corporate/portfolio move with limited direct impact on Novo Nordisk’s operational outlook. Novo Holdings investment
• Negative Sentiment: Eli Lilly launched its once‑daily oral GLP‑1 (Foundayo) broadly in the U.S., increasing competitive pressure on Novo’s market share and pricing power in weight‑loss treatments. Foundayo availability
• Negative Sentiment: Reports of cheap semaglutide generics in India are eroding pricing power in key markets and could weigh on longer‑term revenue if generics expand beyond regional markets. India generics report
• Negative Sentiment: UBS and other analysts warn Q1 results (May 6) will be the first meaningful read on economics at new, lower GLP‑1 price points; coupled with a disappointing CagriSema trial and below‑consensus 2026 guidance earlier this year, this raises near‑term earnings risk. UBS pricing test note
• Negative Sentiment: Media and commentators highlight Eli Lilly pulling ahead in the obesity drug race, which can weigh on sentiment and relative valuation for Novo in the near term. 247WallSt comparison

Wall Street Analyst Weigh In

NVO has been the subject of a number of research analyst reports. Jefferies Financial Group raised Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a report on Thursday, February 12th. Wolfe Research assumed coverage on shares of Novo Nordisk A/S in a research note on Thursday, March 26th. They issued a “peer perform” rating on the stock. Weiss Ratings upgraded Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, April 7th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 24th. Finally, Kepler Capital Markets downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Tuesday, February 24th. Four equities research analysts have rated the stock with a Buy rating and twenty have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $65.56.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.